Effect of ITF2357 on Mucosal Healing in Patients With Moderate-to-severe Active Crohn's Disease
Stopped As no safety warnings were detected, Interim analysis from the first 40 patients recommends to stop the trial for futility
Conditions
Interventions
- DRUG: ITF2357
- OTHER: Placebo
Sponsor
Italfarmaco